{"Q": 1, "answer": "no", "rationale": "The segment does not contain an intensifier or comparative directly modifying a risk-adjective.", "method": "llm_batch", "batch_id": "batch_1_15188", "batch_size": 200, "batch_pos": 64, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
{"Q": 2, "answer": "no", "rationale": "The segment does not contain any high-potency verbs, potent metaphors, critical alert phrases, superlatives + harm nouns, or intensifiers + harm nouns.", "method": "llm_batch", "batch_id": "batch_2_7944", "batch_size": 200, "batch_pos": 52, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
{"Q": 3, "answer": "no", "rationale": "The segment does not contain a moderate verb from the specified list paired with scale/impact information.", "method": "llm_batch", "batch_id": "batch_3_19340", "batch_size": 200, "batch_pos": 30, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
{"Q": 4, "answer": "no", "rationale": "Segment contains no question.", "method": "llm_batch", "batch_id": "batch_4_16448", "batch_size": 200, "batch_pos": 29, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
{"Q": 5, "answer": "no", "rationale": "The segment reports a timeline for testing, lacking explicit calming language.", "method": "llm_batch", "batch_id": "batch_5_14704", "batch_size": 200, "batch_pos": 28, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
{"Q": 6, "answer": "no", "rationale": "No minimiser or scale contrast found.", "method": "llm_batch", "batch_id": "batch_6_17804", "batch_size": 200, "batch_pos": 13, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
{"Q": 7, "answer": "no", "rationale": "Segment does not contain a bare negation.", "method": "llm_batch", "batch_id": "batch_7_19844", "batch_size": 200, "batch_pos": 7, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
{"Q": 8, "answer": "yes", "rationale": "The segment describes a future activity ('late-stage testing would begin').", "method": "llm_batch", "batch_id": "batch_8_15164", "batch_size": 200, "batch_pos": 141, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
